Skip to content

Clinical Effectiveness of iReadMore for People With Alexia

Investigating the Clinical Effectiveness of iReadMore; a Digital Therapy for People With Alexia (Acquired Dyslexia)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04849091
Enrollment
100
Registered
2021-04-19
Start date
2021-03-15
Completion date
2024-04-30
Last updated
2023-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alexia, Aphasia, Brain Injuries, Dementia, Stroke

Keywords

Digital, Therapy, Reading disorder, Alexia, Dyslexia, Rehabilitation

Brief summary

iReadMore will provide an app-based therapy for people with pure or central alexia. This study aims to test the clinical effectiveness of iReadMore for improving reading accuracy and speed in real world users of the therapy.

Detailed description

iReadMore is a self-led therapy app for improving single word reading accuracy and speed in individuals with acquired reading impairments. iReadMore has been demonstrated to improve reading speed and accuracy in pure and central alexias (Woodhead et al., 2013, 2018). iReadMore therapy is not expected to improve reading for the remaining alexia subtypes. iReadMore includes 590 of the most frequently written words from the SUBTLEX lexical database (Brysbaert and New, 2009). High frequency words were chosen to maximise the relevance (ecological utility) of the training to everyday life. The therapy mechanism relies on mass practice of cross-modal, paired associate learning (Holcomb and Anderson, 1993) based on the Triangle Model approach to reading. Untrained words will not be affected, and thus word reading improvements are not expected to generalise beyond trained items. The therapy utilises gamification and is designed to be accessible in order to drive motivation and engagement for the user group. iReadMore is downloadable via the Google Play store on Android tablet devices. iReadMore is a CE-marked class 1 medical device that was developed by the Neurotherapeutics Group, University College London. An online roll-out trial will be conducted to evaluate the clinical effectiveness of iReadMore with a study population of real world users. The therapy will be evaluated in a clinical population with a reading impairment of any acquired cause (such as stroke or brain injury). Participants will self-enrol in the study through the app, which has been co-designed to ensure accessibility to this user group. A within-participant evaluation of trained versus untrained items will investigate the clinical effectiveness of the therapy for improving reading speed and accuracy. The primary outcomes are improvements in single word reading accuracy and speed. Interval testing will be conducted after every 5 hours of therapy. The secondary outcomes are self-reported Activities of Daily Living and a series of qualitative questions. Further analyses will be conducted on alexia subtypes and the influence of therapy dose and intensity on the therapeutic outcomes. Ethical approval for the iReadMore roll-out trial was obtained from the UCL Research Ethics Committee (ID: 7609/001).

Interventions

DEVICEiReadMore

Digital Alexia Therapy

Sponsors

Medical Research Council
CollaboratorOTHER_GOV
University College, London
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Over 18 years old * Diagnosed with stroke, dementia, brain injury or brain tumour * Diagnosed or self-diagnosed with impaired reading ability * Willing and able to give informed consent for participation in the study

Exclusion criteria

* History of developmental reading or speech and language disability

Design outcomes

Primary

MeasureTime frameDescription
Word Reading Test - Change in Reading Accuracy and Speed from baseline to 20 hoursAt baseline and after every 5 hours of therapy up to a maximum dose of 50 hours. Primary outcome is change from baseline to 20 hours.Change in single word reading accuracy and speed will be assessed in a Word Reading Test (WRT) delivered in the app. At interval tests, the WRT will include both trained and untrained words to investigate the treatment-specific effects.

Secondary

MeasureTime frameDescription
Participant-Reported Outcome Measures - Activities of Daily Living (ADL)At baseline and after every 10 hours of therapy up to a maximum dose of 50 hoursActivities of Daily Living - Participants are asked to rate how easy they find completing a series of everyday tasks, including language and non-language related tasks. Responses are reported using a 7-point Likert scale from 0 to 6 denoting 'Very Easy' to 'Very Hard'.
Participant-Reported Outcome Measures - Qualitative QuestionsAt baseline and after every 10 hours of therapy up to a maximum dose of 50 hoursQualitative Questions - participants are also asked three open text questions on their experiences of the therapy and their reading abilities at that point in time.

Countries

United Kingdom

Contacts

Primary ContactAlexander P Leff, Professor
a.leff@ucl.ac.uk02076791177
Backup ContactThomas Langford, MSc
thomas.langford.18@ucl.ac.uk07972267097

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026